No Data
Private Companies Are Bio-Thera Solutions, Ltd.'s (SHSE:688177) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥1.2b Last Week
Biotech: Biotech 2024 Annual Report Summary
Biotech: Biotech 2024 Annual Report
Biotech 2024 Annual Report Summary
Biotech 2024 Annual Report
Bio-Thera Solutions (688177.SH): Net loss of 0.51 billion yuan in 2024.
On April 8, Gelonghui reported that Bio-Thera Solutions (688177.SH) published its annual report for 2024, revealing revenue of 0.743 billion yuan, a year-on-year increase of 5.44%; the net income attributable to shareholders of the listed company was -0.51 billion yuan; basic EPS was -1.23 yuan. The main reason for the year-on-year revenue growth is the continuous increase in the sales of Guleli (Adalimumab) injection, along with the new overseas supply business for Tocilizumab injections; however, the overseas partners are still in the early stage of development, resulting in a relatively small overall increase in revenue.
Bio-Thera Solutions, Ltd.'s (SHSE:688177) 26% Price Boost Is Out Of Tune With Revenues
